Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 May 2004

Safety and tolerability of the combination therapy with pegylatedinterferon alfa-2a (Pegasys®) and ribavirin (Copegus®) in patientswith chronic hepatitis C in Poland – interim analysis of data fromEAP program

Marta Wawrzynowicz-Syczewska, Marek Wasilewski, Hanna Trocha, Ewa Topczewska-Staubach, Krzysztof Tomasiewicz, Katarzyna Świętek, Katarzyna Szamotulska, Katarzyna Sikorska, Andrzej Horban, Marek Beniowski, Hanna Berak, Beata Bolewska, Anna Boroń-Kaczmarska, Janusz Cianciara, Andrzej Cieśla, Jacek Gąsiorowski, Andrzej Gietka, Ewa Gliwińska, Andrzej Gładysz, Zbigniew Gonciarz, Waldemar Halota, Małgorzata Inglot, Urszula Janas-Skulina, Ewa Janczewska-Kazek, Jolanta Jaskowska, Krzysztof Jurczyk, Jacek Juszczyk, Brygida Knysz, Wiesław Kryczka, Jan Kuydowicz, Anna Lakomy, Beata Logiewa-Bazger, Małgorzata Zejc-Bajsarowicz, Dorota Zarębska-Michaluk, Witold Wrodycki, Anna Łyczak, Tomasz Mach, Włodzimierz Mazur, Zofia Michalska, Roma Modrzewska, Khalil Nazzal, Paweł Pabjan, Anna Piekarska, Paweł Piszko

Med Sci Monit 2004; 10(1): 12-16 :: ID: 11832


Open-label, multicenter extended availability program with peginterferon alfa-2a used in combination with ribavirin in patients with CHC in Poland was analysed. Finally, 572 patients were enrolled. The interim analysis of safety and tolerability was performed in 190 patients whose data were available after 72 weeks of observation. Mean hemoglobin level was 14.8 g/dl and decreased to week 24, then remain stable until the end of therapy and returned to the baseline value. Lekocytes level in week 2 decreased, reach a plateau in week 8 and return to baseline values at end observation. Similar phenomenon was observed with neutrophils. Platelet count during the treatment fell gradually in week 8 and remained stable. Reported adverse events requiring PEGASYS® or COPEGUS
® dose reduction were also analyzed. The most frequent adverse effect leading to the reduction of peginterferon alfa-2a dose was reduction. It was noted in 16 patients out of 18, who had the doses reduced because of adverse effects. Only in 5 patients, the dose was reduced because of depression or anxiety. Combined therapy was generally well-tolerated, preliminary analysis data confirms similar tolerability profile to that observed in phase III clinical trials.

Keywords: combination therapy with pegylated interferon alfa-2a and ribavirin, safety and tolerability, chronic hepatitis C



01 January 2023 : Editorial  

Editorial: Current Status of Two Adjuvanted Malaria Vaccines and the World Health Organization (WHO) Strategy to Eradicate Malaria by 2030

Dinah V. Parums
Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA

DOI: 10.12659/MSM.939357

Med Sci Monit 2023; 29:e939357


26 January 2023 : Editorial  

Editorial: The XBB.1.5 (‘Kraken’) Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread

Med Sci Monit In Press; DOI: 10.12659/MSM.939580  

19 January 2023 : Clinical Research  

Evaluation of Health-Related Quality of Life and Mental Health in 729 Medical Students in Indonesia During ...

Med Sci Monit In Press; DOI: 10.12659/MSM.938892  

27 December 2022 : Clinical Research  

Effect of Physiotherapy to Correct Rounded Shoulder Posture in 30 Patients During the COVID-19 Pandemic in ...

Med Sci Monit 2022; 28:e938926

In Press

27 Jan 2023 : Database Analysis  

Association Between Neutrophil-Lymphocyte Ratio and All-Cause Mortality in Critically Ill Patients with Chr...

Med Sci Monit In Press; DOI: 10.12659/MSM.938554  

27 Jan 2023 : Clinical Research  

Proposal for a Simple Equation for Limb Muscle Weight Calculation

Med Sci Monit In Press; DOI: 10.12659/MSM.938606  

26 Jan 2023 : Editorial  

Editorial: The XBB.1.5 (‘Kraken’) Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread

Med Sci Monit In Press; DOI: 10.12659/MSM.939580  

20 Jan 2023 : Clinical Research  

A Study of 42 Partially Edentulous Patients with Single-Crown Restorations and Implants to Compare Bone Los...

Med Sci Monit In Press; DOI: 10.12659/MSM.939225  

Most Viewed Current Articles

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750